Pipeline Database

UB439

Search clinical-stage assets by therapeutic area, modality, target, indication, stage and territory — then inquire on any row that fits your brief.

Submit a Project Finished Dosage Form DB

UB439

IndicationsAutism spectrum disorder

ClinicalCN - Early Phase

TherapeuticsNeurology

ModalitiesProtein

Exclusive Summary

**First-in-Class Innovation & Delivery**: UB439 is a stress-adaptive protein therapy utilizing a **Nasal Spray formulation** (UBD002 series), significantly enhancing compliance for comprehensive pediatric ASD treatment compared to injectables.
**Disease-Modifying Mechanism**: Unlike symptomatic treatments, it targets neuroinflammation (NF-κB pathway) and multi-target neural network repair, aiming to address the underlying pathology of autism.
**Clinical Readiness**: UB439 has obtained **Ethical Approval for Investigator-Initiated Trials (IIT)**, positioning it for rapid generation of human proof-of-concept data.
**Scalable Manufacturing**: Leveraging a standardized "cell-free, non-exosomal" platform with high batch consistency (Pearson > 0.94), it overcomes the scalability and stability bottlenecks typical of biologic therapies.

Asset Materials

UB439 Asset Materials

How can we help you?

Receive insights into the latest events and regulatory updates

Sent directly to your email

Get industry insights and Unibest news here